Title:
PREPARATION AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS
Document Type and Number:
WIPO Patent Application WO/2017/150725
Kind Code:
A1
Abstract:
Provided is a novel cancer treatment method using an FGFR inhibitor that exhibits a very good antitumor effect and little adverse effect. Also provided are a combination preparation for treating malignant tumors that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and one or a plurality of other compounds having an antitumor effect or pharmaceutically acceptable salts thereof; and a pharmaceutical composition that contains both agents. The following are also provided: an antitumor effect potentiator, an antitumor agent, a kit for treating malignant tumors, etc. that contain the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
Inventors:
MIURA AKIHIRO (JP)
SOOTOME HIROSHI (JP)
SOOTOME HIROSHI (JP)
Application Number:
PCT/JP2017/008599
Publication Date:
September 08, 2017
Filing Date:
March 03, 2017
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/519; A61K31/337; A61K31/436; A61K31/4375; A61K31/4412; A61K31/513; A61K31/53; A61K31/7068; A61K31/7072; A61K33/243; A61K45/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| WO2013108809A1 | 2013-07-25 | |||
| WO2014172644A2 | 2014-10-23 | |||
| WO2014138364A2 | 2014-09-12 | |||
| WO2012137870A1 | 2012-10-11 |
Foreign References:
| JP2011524888A | 2011-09-08 |
Other References:
XIE, LIANG ET AL.: "FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547", CLINICAL CANCER RESEARCH, vol. 19, no. 9, 1 May 2013 (2013-05-01), pages 2572 - 2583, XP055332524
BYRON, SARA A. ET AL.: "Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 22, no. 9, November 2012 (2012-11-01), pages 1517 - 1526, XP009172165
See also references of EP 3424505A4
BYRON, SARA A. ET AL.: "Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 22, no. 9, November 2012 (2012-11-01), pages 1517 - 1526, XP009172165
See also references of EP 3424505A4
Attorney, Agent or Firm:
HIRAKI Yusuke et al. (JP)
Download PDF: